安杰思：去年归母净利润2.23亿元，同比下降24.06%

Core Viewpoint - Anjiesi reported a decline in revenue and net profit for the fiscal year 2025, attributed to industry challenges and increased competition in the minimally invasive endoscopic treatment sector [1] Financial Performance - The company achieved total operating revenue of 597 million yuan in 2025, representing a year-on-year decrease of 6.19% [1] - The net profit attributable to shareholders was 223 million yuan, reflecting a year-on-year decline of 24.06% [1] Industry Context - The medical device industry faced pressures from domestic centralized procurement policies and overseas tariff regulations, impacting the company's main business [1] - Increased competition in the minimally invasive treatment field contributed to the company's performance challenges in 2025 [1]